Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1958 1
1968 1
1970 1
1974 2
1980 2
1981 2
1982 2
1983 2
1984 1
1986 2
1987 2
1988 5
1989 1
1990 4
1991 3
1992 12
1993 9
1994 14
1995 6
1996 8
1997 4
1998 10
1999 4
2000 8
2001 9
2002 9
2003 6
2004 10
2005 7
2006 9
2007 5
2008 12
2009 3
2010 6
2011 7
2012 7
2013 7
2014 11
2015 9
2016 5
2017 6
2018 4
2019 8
2020 12
2021 10
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Pharmacology.
Mason JM, O'Brien ME, Koehl JL, Ji CS, Hayes BD. Mason JM, et al. Emerg Med Clin North Am. 2022 Nov;40(4):771-792. doi: 10.1016/j.emc.2022.06.012. Epub 2022 Oct 7. Emerg Med Clin North Am. 2022. PMID: 36396221 Review.
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. Kelly K, et al. J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324372 Clinical Trial.
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. O'Brien ME, et al. Ann Oncol. 2004 Mar;15(3):440-9. doi: 10.1093/annonc/mdh097. Ann Oncol. 2004. PMID: 14998846 Free article. Clinical Trial.
Risk of Serotonin Syndrome with Isoniazid.
O'Brien ME, Gandhi RG, Kotton CN, Adamsick ML. O'Brien ME, et al. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01455-20. doi: 10.1128/AAC.01455-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33077663 Free PMC article. No abstract available.
Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Kumar R, Collins D, Dolly S, McDonald F, O'Brien MER, Yap TA. Kumar R, et al. Curr Probl Cancer. 2017 Mar-Apr;41(2):111-124. doi: 10.1016/j.currproblcancer.2016.12.002. Epub 2016 Dec 23. Curr Probl Cancer. 2017. PMID: 28214087 Review.
Malignant mesothelioma--the UK experience.
O'Brien ME. O'Brien ME. Lung Cancer. 2004 Aug;45 Suppl 1:S133-5. doi: 10.1016/j.lungcan.2004.04.024. Lung Cancer. 2004. PMID: 15261447 Review.
255 results